Gimv co-leads EUR 43.5 million financing of Breath Therapeutics – Funding will be used to execute pivotal trials

Breath Therapeutics BV today announced the closing of a series A financing round. Thereby the company secured funding of EUR 43.5 million. The round was co-led by Gimv and Sofinnova Partners, which were joined by Gilde Healthcare. PARI Pharma financially supports the program. This financing, which is one of the larger rounds for a European […]

Continue Reading

Upcoming Event